TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
TWD 9.58
(-0.62%)
TWD 9.58
(-0.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -174.69 Million TWD | 19.55% |
| 2022 | -217.15 Million TWD | -124.78% |
| 2021 | 876.24 Million TWD | 317.01% |
| 2020 | -403.78 Million TWD | -40.67% |
| 2019 | -287.03 Million TWD | -11.08% |
| 2018 | -258.39 Million TWD | -199.22% |
| 2017 | 260.42 Million TWD | 209.56% |
| 2016 | -237.71 Million TWD | 44.87% |
| 2015 | -431.2 Million TWD | -5.53% |
| 2014 | -408.59 Million TWD | 17.72% |
| 2013 | -496.58 Million TWD | -0.07% |
| 2012 | -496.24 Million TWD | -129.85% |
| 2011 | -215.89 Million TWD | 52.14% |
| 2010 | -451.08 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -58.8 Million TWD | 31.03% |
| 2024 Q2 | 65.01 Million TWD | 184.56% |
| 2023 Q3 | -8.32 Million TWD | -145.71% |
| 2023 FY | -174.69 Million TWD | 19.55% |
| 2023 Q1 | -50.37 Million TWD | 52.7% |
| 2023 Q2 | 18.22 Million TWD | 136.17% |
| 2023 Q4 | -85.26 Million TWD | -923.85% |
| 2022 Q3 | 13.98 Million TWD | 114.51% |
| 2022 FY | -217.15 Million TWD | -124.78% |
| 2022 Q1 | -28.24 Million TWD | 74.34% |
| 2022 Q2 | -96.37 Million TWD | -241.18% |
| 2022 Q4 | -106.51 Million TWD | -861.81% |
| 2021 Q4 | -110.06 Million TWD | -56.6% |
| 2021 FY | 876.24 Million TWD | 317.01% |
| 2021 Q2 | 1.12 Billion TWD | 3433.1% |
| 2021 Q3 | -70.28 Million TWD | -106.26% |
| 2021 Q1 | -33.68 Million TWD | 68.22% |
| 2020 Q3 | -88.39 Million TWD | -47.09% |
| 2020 Q1 | -52.84 Million TWD | 36.9% |
| 2020 Q4 | -105.97 Million TWD | -19.89% |
| 2020 FY | -403.78 Million TWD | -40.67% |
| 2020 Q2 | -60.09 Million TWD | -13.73% |
| 2019 Q3 | -66.9 Million TWD | 1.4% |
| 2019 Q1 | -58.63 Million TWD | 30.26% |
| 2019 Q2 | -67.85 Million TWD | -15.74% |
| 2019 Q4 | -83.74 Million TWD | -25.17% |
| 2019 FY | -287.03 Million TWD | -11.08% |
| 2018 Q1 | -46.76 Million TWD | 35.55% |
| 2018 Q4 | -84.06 Million TWD | -25.96% |
| 2018 Q3 | -66.74 Million TWD | -9.73% |
| 2018 Q2 | -60.82 Million TWD | -30.08% |
| 2018 FY | -258.39 Million TWD | -199.22% |
| 2017 FY | 260.42 Million TWD | 209.56% |
| 2017 Q2 | 452.09 Million TWD | 1008.32% |
| 2017 Q1 | -49.77 Million TWD | 14.13% |
| 2017 Q3 | -69.34 Million TWD | -115.34% |
| 2017 Q4 | -72.55 Million TWD | -4.63% |
| 2016 Q2 | -36.88 Million TWD | 53.35% |
| 2016 Q3 | -63.8 Million TWD | -73.01% |
| 2016 FY | -237.71 Million TWD | 44.87% |
| 2016 Q4 | -57.96 Million TWD | 9.16% |
| 2016 Q1 | -79.06 Million TWD | 37.43% |
| 2015 Q2 | -109.75 Million TWD | -32.01% |
| 2015 Q4 | -126.34 Million TWD | -12.86% |
| 2015 Q3 | -111.95 Million TWD | -2.0% |
| 2015 Q1 | -83.14 Million TWD | 38.04% |
| 2015 FY | -431.2 Million TWD | -5.53% |
| 2014 Q2 | -114.66 Million TWD | -124.75% |
| 2014 Q1 | -51.01 Million TWD | 70.3% |
| 2014 Q4 | -134.18 Million TWD | -23.42% |
| 2014 FY | -408.59 Million TWD | 17.72% |
| 2014 Q3 | -108.72 Million TWD | 5.18% |
| 2013 Q2 | -103.62 Million TWD | -38.08% |
| 2013 Q4 | -171.78 Million TWD | -17.56% |
| 2013 Q3 | -146.12 Million TWD | -41.01% |
| 2013 FY | -496.58 Million TWD | -0.07% |
| 2013 Q1 | -75.04 Million TWD | 58.0% |
| 2012 Q4 | -178.66 Million TWD | -43.79% |
| 2012 Q3 | -124.25 Million TWD | 0.0% |
| 2012 FY | -496.24 Million TWD | -129.85% |
| 2011 FY | -215.89 Million TWD | 52.14% |
| 2010 FY | -451.08 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| GeneReach Biotechnology Corp. | -229.28 Million TWD | 23.807% |
| Sunmax Biotechnology Co., Ltd. | 894.79 Million TWD | 119.524% |
| Lukas Biomedical Inc. | -43.56 Million TWD | -301.054% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 281.85 Million TWD | 161.983% |
| Level Biotechnology Inc. | 67.55 Million TWD | 358.614% |
| Sagittarius Life Science Corp | -64.37 Million TWD | -171.373% |
| NeoCore Technology Co., Ltd. | -84.94 Million TWD | -105.664% |
| TaiMed Biologics Inc. | -166.23 Million TWD | -5.094% |
| GlycoNex Incorporation | -259.86 Million TWD | 32.773% |
| VBI | -16.13 Million TWD | -982.935% |
| Taiwan Advance Bio-Pharmaceutical Inc. | -2.25 Million TWD | -7654.061% |
| SynCore Biotechnology Co.,Ltd | -45.5 Million TWD | -283.937% |
| Genomics BioSci & Tech. Co.,Ltd. | -84.99 Million TWD | -105.543% |
| Visgeneer Inc. | -21.15 Million TWD | -725.649% |
| Mycenax Biotech Inc. | -602.1 Million TWD | 70.985% |
| G&E Herbal Biotechnology Co., Ltd. | 80.68 Million TWD | 316.522% |
| Neith Corporation | -48.85 Million TWD | -257.594% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -6.61 Million TWD | -2542.95% |
| Enimmune corporation | -243.47 Million TWD | 28.248% |
| TaiRx, Inc. | -214.69 Million TWD | 18.629% |
| CHO Pharma, Inc. | -268.99 Million TWD | 35.056% |
| EirGenix Inc. | -1.03 Billion TWD | 83.071% |
| BioLASCO Taiwan Co., Ltd. | 63.33 Million TWD | 375.833% |
| Sunny Pharmtech Inc. | -72.09 Million TWD | -142.314% |
| Advagene Biopharma Co., Ltd. | -93.33 Million TWD | -87.172% |
| BioGend Therapeutics Co., Ltd. | -176.54 Million TWD | 1.043% |
| Feng Chi Biotech Corp. | 24.16 Million TWD | 823.032% |
| RBC Bioscience Corporation | 14.53 Million TWD | 1301.589% |
| BiOptic Inc. | 44.05 Million TWD | 496.566% |
| Anti-Microbial Savior BioteQ Co., Ltd | -56.74 Million TWD | -207.845% |
| BRIM Biotechnology, Inc. | -694.12 Million TWD | 74.832% |
| Shine-On BioMedical Co.,Ltd. | -62.68 Million TWD | -178.702% |
| Great Novel Therapeutics Biotech & Medicals | -65.81 Million TWD | -165.419% |
| Syngen Biotech Co.,Ltd. | 334.08 Million TWD | 152.292% |
| Medigen Vaccine Biologics Corporation | -1.21 Billion TWD | 85.608% |
| Bio Preventive Medicine Corp. | -70.58 Million TWD | -147.512% |
| Lin BioScience, Inc. | -1.09 Billion TWD | 84.072% |
| NaviFUS Corp. | -76.42 Million TWD | -128.586% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -93.95 Million TWD | -85.939% |
| Sinew Pharma Inc. | -186.25 Million TWD | 6.203% |
| Andros Pharmaceuticals Co.,Ltd | -67.69 Million TWD | -158.06% |
| Greenyn Biotechnology Co., Ltd | 159.81 Million TWD | 209.312% |
| Lumosa Therapeutics Co., Ltd. | -375.62 Million TWD | 53.491% |
| AP Biosciences Inc | -347.47 Million TWD | 49.724% |
| Medigen Biotechnology Corp. | -1.23 Billion TWD | 85.832% |
| 3D Global Biotech Inc. | -62.85 Million TWD | -177.949% |
| Pharmosa Biopharm Inc. | -2.82 Million TWD | -6086.225% |
| Intech Biopharm Corporation | -304.39 Million TWD | 42.608% |
| Oneness Biotech Co., Ltd. | -1.09 Billion TWD | 84.069% |
| Eusol Biotech Co.,Ltd. | -41.48 Million TWD | -321.144% |
| TWi Biotechnology, Inc. | -169.55 Million TWD | -3.033% |
| Ever Supreme Bio Technology Co., Ltd | 337.73 Million TWD | 151.727% |
| TCI GENE Inc. | 10.04 Million TWD | 1838.471% |
| MegaPro Biomedical Co., Ltd | -127.25 Million TWD | -37.28% |
| Senhwa Biosciences, Inc. | -311.11 Million TWD | 43.847% |
| Taiwan Bio Therapeutics Co., Ltd | -212.2 Million TWD | 17.674% |
| NatureWise Biotech & Medicals Corporation | 3.43 Million TWD | 5187.333% |
| PharmaEngine, Inc. | 277.18 Million TWD | 163.027% |
| Savior Lifetec Corporation | -2.42 Million TWD | -7118.967% |
| OBI Pharma, Inc. | -2.08 Billion TWD | 91.64% |
| Meribank Biotech Co., Ltd | -123.15 Million TWD | -41.854% |
| Acepodia, Inc. | -435.97 Million TWD | 59.929% |
| Caliway Biopharmaceuticals Co., Ltd. | -487.95 Million TWD | 64.198% |